Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Diabetes patients face cardiovascular risks comparable to non-diabetics with heart attack history.
• Conventional glycemic control primarily benefits microvascular health, not macrovascular outcomes or mortality.
• Postprandial hyperglycemia is a potential independent risk factor for cardiovascular disease in diabetes.

Purpose of the Study:

• To review the potential cardiovascular benefits of mitiglinide in type 2 diabetes.
• To explore mitiglinide's role in managing postprandial hyperglycemia and associated risks.
• To summarize current insights on mitiglinide for cardiovascular disease prevention in diabetes.

Main Methods:

• Literature review of studies on diabetes, cardiovascular complications, glycemic control, and mitiglinide.
• Analysis of evidence regarding the impact of glycemic control on macrovascular and microvascular outcomes.
• Examination of mitiglinide's pharmacological effects, including insulin secretion, oxidative stress, and inflammation.

Main Results:

• Intensive glycemic control shows limited impact on macrovascular complications and mortality.
• Mitiglinide effectively reduces postprandial glucose levels in type 2 diabetes.
• Mitiglinide demonstrates cardioprotective effects by reducing oxidative stress and inflammation.

Conclusions:

• Mitiglinide shows promise in managing postprandial hyperglycemia and may play a role in cardiovascular disease prevention for type 2 diabetes patients.
• Further long-term, randomized trials are needed to confirm mitiglinide's clinical cardiovascular outcomes.
• Mitiglinide's favorable effects on vascular endothelial function, especially with pioglitazone, warrant further investigation.